Antagonism of IL-4 signaling by a phosphodiesterase-4 inhibitor, rolipram, in human T cells

被引:7
|
作者
Markova, Tzvetanka Petrova
Niwa, Atsuko
Yamanishi, Hiromichi
Aragane, Yoshinori
Higashino, Hideaki
机构
[1] Int Tougenkai Inst Phototherapy & Immunotherapy S, Dermatol Sect, Nishi Ku, Osaka 5500012, Japan
[2] Kinki Univ, Sch Med, Dept Pharmacol, Osakasayama, Japan
[3] Hirakata Ryoikuen, Hirakata, Osaka, Japan
关键词
AP-1; components; cAMP; IL-4; IL-5; PDE4; inhibitors; PKA; rolipram; signal transduction; T cells;
D O I
10.1159/000099465
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Phosphodiesterase (PDE4) inhibitors prevent breakdown of cAMP and affect the increase in cellular levels of cAMP, which is known to regulate immune cell functions. Because IL-4 plays a causal role in the pathogenesis of allergic disorders, we were interested to study the modulatory mechanisms of a PDE4 inhibitor, rolipram, in IL-4-mediated signaling in T cells. Methods: Human peripheral T cells were stimulated with IL-4 in combination with rolipram, and RTPCR was performed using primers specific for IL-5. To monitor activation of transcription factors, immunostaining was employed. Results: Rolipram or a cAMP-analogue, 8- Br-cAMP, significantly downregulated IL-4-induced expression of IL-5 mRNA. The rolipram-induced inhibition of IL-5 mRNA was mediated by activation of protein kinase A (PKA), because rolipram-downregulated mRNA expression of IL-5 was restored by PKA inhibitors. Immunostaining revealed that rolipram interfered with IL-4-induced nuclear translocation of activator protein (AP)-1 components. Conclusions: This is the first demonstration of suppression of IL-4 signaling by PDE4 inhibitors via prevention of nuclear translocation of AP-1. Copyright (c) 2007 S. Karger AG, Basel
引用
收藏
页码:216 / 224
页数:9
相关论文
共 50 条
  • [31] Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
    Schafer, P. H.
    Parton, A.
    Gandhi, A. K.
    Capone, L.
    Adams, M.
    Wu, L.
    Bartlett, J. B.
    Loveland, M. A.
    Gilhar, A.
    Cheung, Y-F
    Baillie, G. S.
    Houslay, M. D.
    Man, H-W
    Muller, G. W.
    Stirling, D. I.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (04) : 842 - 855
  • [32] PET of (R)-11C-Rolipram Binding to Phosphodiesterase-4 Is Reproducible and Sensitive to Increased Norepinephrine in the Rat Heart
    Thomas, Adam J.
    DaSilva, Jean N.
    Lortie, Mireille
    Renaud, Jennifer M.
    Kenk, Miran
    Beanlands, Rob S.
    deKemp, Robert A.
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (02) : 263 - 269
  • [33] Biochemical evidence on positive effects of rolipram a phosphodiesterase-4 inhibitor in malathion-induced toxic stress in rat blood and brain mitochondria
    Rezvanfar, Mohammad Ali
    Rezvanfar, Mohammad Amin
    Ranjbar, Akram
    Baeeri, Maryam
    Mohammadirad, Azadeh
    Abdollahi, Mohammad
    PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY, 2010, 98 (01) : 135 - 143
  • [34] High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast
    Bethke, T. D.
    Lahu, G.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (01) : 51 - 57
  • [35] The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation
    Hedde, Joseph R.
    Hanks, Ashley N.
    Schmidt, Christopher J.
    Hughes, Zoe A.
    BRAIN BEHAVIOR AND IMMUNITY, 2017, 64 : 285 - 295
  • [36] Rolipram, a Phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells
    Eun Sook Cho
    Ja Heon Yu
    Mi Sun Kim
    Mijung Yim
    Archives of Pharmacal Research, 2004, 27 : 1258 - 1262
  • [37] Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse clavarial cells
    Cho, ES
    Yu, JH
    Kim, MS
    Yim, MJ
    ARCHIVES OF PHARMACAL RESEARCH, 2004, 27 (12) : 1258 - 1262
  • [38] Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats
    Makhay, MM
    Houslay, MD
    O'Donnell, JM
    PSYCHOPHARMACOLOGY, 2001, 158 (03) : 297 - 304
  • [39] IL-4: An important cytokine in determining the fate of T cells
    Silva-Filho J.L.
    Caruso-Neves C.
    Pinheiro A.A.S.
    Biophysical Reviews, 2014, 6 (1) : 111 - 118
  • [40] Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis
    Kitahara, Yasumi
    Hojo, Seiichiro
    Nomoto, Maiko
    Onozuka, Daisuke
    Furue, Masutaka
    Hagihara, Akihito
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (05) : 466 - 470